Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 1;4(2):125-135.
doi: 10.1177/2474126419893829. Epub 2020 Jan 6.

American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema

Yoshihiro Yonekawa  1 , Yasha S Modi  2 , Leo A Kim  3 , Dimitra Skondra  4 , Judy E Kim  5 , Charles C Wykoff  6
Affiliations

American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema

Yoshihiro Yonekawa et al. J Vitreoretin Dis. .

Abstract

Purpose: Nonproliferative (NPDR) and proliferative diabetic retinopathy (PDR) without diabetic macular edema (DME) affect millions of individuals living with diabetes throughout the world. There is increasing data on various management strategies for such patients, but there is limited consensus on how the data should be adopted into clinical practice.

Methods: This literature review and editorial presents and synthesizes the current evidence for various management paradigms for NPDR and PDR without DME.

Results: Retina specialists are an integral member of the diabetes management team, and should encourage patients on the importance of glycemic and cardiovascular optimization for both systemic and retinopathy risk factor reduction. The diabetic retinopathy severity scale (DRSS) is now an approvable endpoint for clinical trials in the United States, therefore becoming more clinically relevant. For PDR without DME, the Diabetic Retinopathy Study (DRS) and the Early Treatment Diabetic Retinopathy Study (ETDRS) established the standard of care with panretinal photocoagulation (PRP). Laser parameters have since evolved to include less intense and earlier intervention. Studies have recently demonstrated that anti-vascular endothelial growth factor (VEGF) treatment of PDR is effective at regressing neovascularization and improving DRSS levels in many patients. Further evidence is required to determine optimal treatment frequency, duration, and retreatment criteria, in the real world. There are concerns for adverse events in patients being lost to follow up during anti-VEGF treatment. For NPDR without DME, the standard of care has been a wait-and-watch approach. Data within the DRS and the ETDRS suggest that PRP for severe NPDR can be an option for select patients as well. Multiple clinical trials have now demonstrated that anti-VEGF treatment can improve the DRSS score in NPDR. Further studies are required to assess whether this positively affects long-term visual outcomes, and whether the benefits outweigh the risks in the real world for routine use.

Conclusions: There is cumulative evidence demonstrating the efficacy of various treatment options for NPDR and PDR without DME. Currently, patients would most likely benefit from thoughtful management strategies that are tailored to the individual patient.

Keywords: diabetes mellitus; diabetic retinopathy; diabetic retinopathy severity scale; intravitreal injection; laser photocoagulation; nonproliferative diabetic retinopathy; panretinal photocoagulation; proliferative diabetic retinopathy; vascular endothelial growth factor.

PubMed Disclaimer

Conflict of interest statement

Consultant for Alcon (Y.Y.), Adverum (C.C.W.), Aerpio (C.C.W.), Alimera (C.C.W., Y.S.M.), Allegro (C.C.W.), Allergan (C.C.W., Y.S.M.), Apellis (C.C.W.), Bayer (C.C.W.), Clearside Biomedical (C.C.W., J.E.K.), EyePoint (C.C.W.), Genentech/Roche (C.C.W., J.E.K., Y.S.M.), Kodiak (C.C.W., J.E.K.), Notal Vision (J.E.K.), Novartis (C.C.W., J.E.K.), ONL Therapeutics (C.C.W.), PolyPhotonix (C.C.W.), Recens Medical (C.C.W.), Regeneron (C.C.W.), Regenxbio (C.C.W.), Santen (C.C.W.).

References

    1. Mazhar K, Varma R, Choudhury F, McKean-Cowdin R, Shtir CJ, Azen SP; Los Angeles Latino Eye Study Group. Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. Ophthalmology. 2011;118(4):649–655. doi:10.1016/j.ophtha.2010.08.003 - PMC - PubMed
    1. Willis JR, Doan QV, Gleeson M, et al. Vision-related functional burden of diabetic retinopathy across severity levels in the United States. JAMA Ophthalmol. 2017;135(9):926–932. doi:10.1001/jamaophthalmol.2017.2553 - PMC - PubMed
    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report , 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017.
    1. National Eye Institute. Diabetic retinopathy. https://nei.nih.gov/eyedata/diabetic. Last updated July 17, 2019. Accessed December 13, 2019.
    1. LeCaire TJ, Palta M, Klein R, Klein BE, Cruickshanks KJ. Assessing progress in retinopathy outcomes in type 1 diabetes: comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care. 2013;36(3):631–637. doi:10.2337/dc12-0863 - PMC - PubMed